• Total revenues of €4.5 million in the 9 months to September 30 2014 (vs. €0.3 million in same period of 2013) 
  • Completion of Aciex Therapeutics, Inc. acquisition significantly strengthens Nicox’s therapeutic development pipeline 
  • Positive phase 3 results for VESNEO (latanoprostene bunod) support strong commercial potential
  • Acquisition of Doliage in France strengthens established revenue streams and marketing infrastructure 
Sophia Antipolis, France.
 
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today provides an update on its revenues and cash position for the first nine months of 2014.
 
Michele Garufi, Chief Executive Officer of Nicox, commented: “In the third quarter of this year, we have achieved important progress in building our therapeutic ophthalmic pipeline, thanks to the positive pivotal phase 3 results for VESNEO and the recently completed acquisition of Aciex Therapeutics, Inc. Nicox now has two product candidates which have completed phase 3 trials and this increases our confidence in our future prospects as a competitive International Ophthalmic Group.”
 
To read the full press release please download the PDF